Last reviewed · How we verify
Activated CIK
Activated CIK (cytokine-induced killer cells) are ex vivo expanded immune cells that target and kill cancer cells through multiple mechanisms including natural killer and T-cell pathways.
Activated CIK (cytokine-induced killer cells) are ex vivo expanded immune cells that target and kill cancer cells through multiple mechanisms including natural killer and T-cell pathways. Used for Cancer (specific indications in phase 2 development not publicly detailed).
At a glance
| Generic name | Activated CIK |
|---|---|
| Sponsor | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. |
| Drug class | Adoptive cell therapy; ex vivo expanded immune cells |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CIK cells are a heterogeneous population of lymphocytes generated by culturing peripheral blood mononuclear cells with interferon-gamma and anti-CD3 antibodies, resulting in cells with both NK and T-cell characteristics. These cells recognize and eliminate tumor cells through perforin/granzyme-mediated cytotoxicity and death receptor pathways. The activated CIK product from Benhealth represents an adoptive cell therapy approach to cancer treatment.
Approved indications
- Cancer (specific indications in phase 2 development not publicly detailed)
Common side effects
- Infusion-related reactions
- Cytokine release syndrome
- Fever
- Fatigue
Key clinical trials
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients (PHASE3)
- Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation (PHASE1, PHASE2)
- Safety and Efficacy of "Immuncell-LC" in TACE Therapy (PHASE2)
- Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor (NA)
- CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. (PHASE1, PHASE2)
- Autologous Killer Cell Therapy in Colon Cancer Patients (PHASE1, PHASE2)
- Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Activated CIK CI brief — competitive landscape report
- Activated CIK updates RSS · CI watch RSS
- Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. portfolio CI